Fig 1.
Flow chart for selection of the study population.
The survey database for Diagnostic Procedure Combination (DPC) was combined with the hospital-based cancer registry and the DPC. * Patients who had a diagnosis and a selected first choice of treatment including best supportive care, were included in the survey database. ** ICD-O-3 topography codes C34.0 (main bronchus), C34.1 (upper lobe of lung), C34.2 (middle lobe of lung), C34.3 (lower lobe of lung), C34.8 (overlapping lesion of lung), C34.9 (lung, not otherwise specified) were identified. *** Patients with de novo stage IV disease as per the UICC classification were identified. **** Adenocarcinomas (ICD-O-3 morphology codes 8140, 8250, 8551, 8260, 8265, 8230, 8253, 8254, 8480, 8333, and 8144), squamous cell carcinomas (8070, 8071, 8072, and 8083), neuroendocrine carcinomas (8041, 8045, and 8013), carcinoid tumors (8240, 8249, 8012, and 8560), sarcomatoid carcinomas (8022, 8032, 8031, 8980, and 8972), other and unclassified carcinomas (8082 and 8023), and salivary gland-type tumors (8430, 8200, and 8562) were identified.
Table 1.
Patient characteristics of each age group.
Fig 2.
First-line treatment choice in all patients.
(a) number of patients and (b) percentage of patients. CDDP, cisplatin; TKI, tyrosine kinase inhibitor; not-recommended Tx, not-recommended chemotherapy; BSC, best supportive care.
Fig 3.
First-line treatment choice by histology.
(a) adenocarcinoma, (b) squamous cell carcinoma, and (c) small cell carcinoma. CDDP, cisplatin; TKI, tyrosine kinase inhibitor; not-recommended Tx, not-recommended chemotherapy; BSC, best supportive care.
Fig 4.
First-line treatment regimens by histology.
(a) adenocarcinoma, (b) squamous cell carcinoma, and (c) small cell carcinoma. CDDP, cisplatin; PEM, pemetrexed; CBDCA, carboplatin; PTX, paclitaxel; Ned, nedaplatin; DTX, docetaxel; not-recommended Tx, not-recommended chemotherapy; BSC, best supportive care; GEM, gemcitabine; nab-PTX, nab-paclitaxel; ETOP, etoposide; CPT-11, irinotecan; AMR, amrubicin.
Fig 5.
First-line choice of cytotoxic chemotherapy in older patients.
(a)-(d) adenocarcinoma, (e)-(h) squamous cell carcinoma, and (i)-(l) small cell carcinoma. Ad, adenocarcinoma; Sq, squamous cell carcinoma; Sm, small cell carcinoma; CDDP, cisplatin; PEM, pemetrexed; CBDCA, carboplatin; PTX, paclitaxel; DTX, docetaxel; not-recommended Tx, not-recommended chemotherapy; GEM, gemcitabine; nab-PTX, nab-paclitaxel; Ned, nedaplatin; ETOP, etoposide; CPT-11, irinotecan; AMR, amrubicin.